Analysts Set AxoGen, Inc. (NASDAQ:AXGN) PT at $35.56

Shares of AxoGen, Inc. (NASDAQ:AXGN) have received a consensus recommendation of “Moderate Buy” from the ten brokerages that are currently covering the stock, Marketbeat reports. One research analyst has rated the stock with a sell recommendation and nine have assigned a buy recommendation to the company. The average twelve-month price objective among analysts that have covered the stock in the last year is $35.5556.

Several research analysts have commented on the stock. JMP Securities set a $34.00 price objective on shares of AxoGen in a report on Thursday, October 30th. Lake Street Capital increased their price target on shares of AxoGen from $30.00 to $40.00 and gave the stock a “buy” rating in a research note on Thursday, December 4th. Wall Street Zen raised AxoGen from a “buy” rating to a “strong-buy” rating in a research report on Friday, January 23rd. HC Wainwright increased their target price on AxoGen from $26.00 to $39.00 and gave the stock a “buy” rating in a research report on Friday, December 5th. Finally, Weiss Ratings restated a “sell (e+)” rating on shares of AxoGen in a research report on Monday, December 29th.

AxoGen Trading Up 3.0%

NASDAQ AXGN opened at $34.93 on Thursday. The stock has a market cap of $1.61 billion, a P/E ratio of -698.60 and a beta of 1.00. AxoGen has a fifty-two week low of $9.22 and a fifty-two week high of $36.00. The stock has a 50 day simple moving average of $32.13 and a two-hundred day simple moving average of $23.03. The company has a debt-to-equity ratio of 0.54, a quick ratio of 2.64 and a current ratio of 4.09.

Insider Activity

In other AxoGen news, Director Amy Mcbride Wendell sold 43,684 shares of the company’s stock in a transaction dated Tuesday, December 16th. The shares were sold at an average price of $29.31, for a total value of $1,280,378.04. Following the sale, the director owned 93,826 shares in the company, valued at approximately $2,750,040.06. This represents a 31.77% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, Director Paul Thomas sold 21,399 shares of AxoGen stock in a transaction that occurred on Tuesday, December 9th. The shares were sold at an average price of $29.61, for a total transaction of $633,624.39. Following the transaction, the director owned 13,528 shares of the company’s stock, valued at $400,564.08. The trade was a 61.27% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. In the last quarter, insiders have sold 324,498 shares of company stock worth $9,721,948. 2.78% of the stock is currently owned by corporate insiders.

Institutional Trading of AxoGen

Institutional investors and hedge funds have recently bought and sold shares of the company. Future Financial Wealth Managment LLC bought a new position in shares of AxoGen in the third quarter worth approximately $27,000. Aquatic Capital Management LLC raised its holdings in AxoGen by 287.8% in the 3rd quarter. Aquatic Capital Management LLC now owns 1,710 shares of the medical equipment provider’s stock worth $31,000 after acquiring an additional 1,269 shares during the last quarter. State of Alaska Department of Revenue bought a new position in AxoGen in the 3rd quarter valued at approximately $43,000. Tower Research Capital LLC TRC boosted its stake in AxoGen by 189.9% during the 2nd quarter. Tower Research Capital LLC TRC now owns 5,079 shares of the medical equipment provider’s stock valued at $55,000 after purchasing an additional 3,327 shares during the last quarter. Finally, FNY Investment Advisers LLC bought a new stake in shares of AxoGen in the 3rd quarter worth $64,000. 80.29% of the stock is currently owned by institutional investors.

About AxoGen

AxoGen, Inc is a Florida-based medical technology company that develops and commercializes surgical solutions for peripheral nerve damage. Founded in 2002 and headquartered in Alachua, Florida, the company focuses on restoring nerve function and improving patient outcomes through innovative biologic and engineered products. AxoGen’s offerings address a range of traumatic and iatrogenic injuries, offering alternatives to traditional nerve autografts.

The company’s core product portfolio includes the Avance® Nerve Graft, a decellularized human nerve allograft designed to bridge nerve gaps without the need for a secondary harvest site, and the Axoguard® Nerve Connector and Protector devices, which facilitate nerve coaptation and protect repaired sites from surrounding scar tissue.